Opaleye Management’s Zosano Pharma Corporation ZSAN Stock Holding History

Opaleye Management’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,857	Closed	-$504K	–	44
2018 Q1	$504K	Buy	+2,857	New	+$956K	0.14%	36
2017 Q3	–	Sell	-1,750	Closed	-$1.73M	–	42
2017 Q2	$1.73M	Sell	1,750 -36	-2%	-$37.2K	0.72%	32
2017 Q1	$2.38M	Buy	+1,786	New	+$2.16M	1.18%	27

Other funds holding ZSAN

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Opaleye Management's ZSAN Position: Q2 2018 in Review

Opaleye Management sold out of Zosano Pharma Corporation (ZSAN) in Q2 2018, closing a stake of 2,857 shares — an estimated $504K sold.

Opaleye Management first reported a position in ZSAN in Q1 2017 and held it in 3 quarters. The position peaked at $2.38M in Q1 2017. 25 funds tracked by Wall St. Rank hold ZSAN as of Q2 2018.

Opaleye Management reported no remaining Zosano Pharma Corporation position as of Q2 2018 after selling out during the quarter.
Opaleye Management sold 2,857 Zosano Pharma Corporation shares in Q2 2018, an estimated $504K.
Opaleye Management first reported a position in Zosano Pharma Corporation in Q1 2017 and held it in 3 quarters.
Opaleye Management's Zosano Pharma Corporation position peaked at $2.38M in Q1 2017.
25 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q2 2018.

Based on Opaleye Management's 13F filing for Q2 2018, filed 14 Aug 2018.